Mifepristone Makers Urgently Appeal Supreme Court to Stop In-Person Pill Rule
The manufacturers of mifepristone, the abortion pill widely used across the US, filed an emergency appeal to the Supreme Court late Saturday seeking to pause a new nationwide rule that requires the medication to be dispensed in person. This urgent legal move came just one day after the conservative 5th US Circuit Court of Appeals reinstated the in-person dispensing mandate, threatening to disrupt access to a critical method of abortion care.
Danco Laboratories, the company behind mifepristone, warned the Supreme Court that the 5th Circuit’s ruling creates “immediate confusion and upheaval” for patients who depend on the medication. Their legal filings highlighted the chaos patients face this weekend if they cannot secure immediate in-person appointments or pharmacy access in states including New York, Minnesota, and Washington.
Why This Matters Now
The appeal — fast-tracked to conservative Justice Samuel Alito — puts the controversial abortion drug back at the heart of the Supreme Court less than two years after the justices upheld its wide availability by rejecting a similar challenge. Since the overturning of Roe v. Wade, medication abortions have surged in popularity and now make up more than 60% of all abortions in the US, according to research by the Guttmacher Institute.
In response to Roe’s fall, the Biden administration finalized rules last year allowing women to receive mifepristone through telehealth visits, ending the longtime in-person doctor visit requirement. But the reinstated rule from the 5th Circuit threatens to roll back these changes nationwide, undermining access just as many conservative states restrict clinic abortions.
Company and Government Push Back
Danco Laboratories urged the Supreme Court to issue an administrative stay immediately, halting the 5th Circuit’s decision to prevent further disruption. They further asked the justices to hear the case fully on the merits.
The company’s attorneys underscored the real-life impact on patients, stressing the time-sensitive nature of accessing abortion medication and questioning how individuals can navigate sudden appointment roadblocks.
Meanwhile, Louisiana and other states have challenged the Biden-era regulations, suing to tighten restrictions and claiming the rules conflict with state abortion bans. A federal district court earlier declined to restrict access pending an FDA safety review of mifepristone.
Safety and Access Debate
Data analyzed by CNN confirms that mifepristone is overwhelmingly safe, with reported side effects far fewer than common medications such as Viagra or penicillin. This strong safety record remains central to the argument for continuing telehealth access without burdensome in-person requirements.
As conservative courts and states intensify efforts to limit abortion access post-Roe, medication abortion has become a lifeline for many across the nation. The Supreme Court’s fast-moving review of this emergency appeal will have immediate consequences for millions of women seeking abortion care.
What to Watch Next
The Supreme Court’s response to Danco’s emergency move is expected shortly and will either maintain the 5th Circuit’s tighter controls or preserve more flexible access established by the FDA and federal government. The outcome will shape abortion pill availability amid growing legal battles across states.
This case marks the latest flashpoint in America’s fractured abortion debate, underscoring how federal courts continue to shape reproductive rights in the post-Roe era.
